metformin has been researched along with Plasmacytoma in 1 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Plasmacytoma: Any discrete, presumably solitary, mass of neoplastic PLASMA CELLS either in BONE MARROW or various extramedullary sites.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cunha Júnior, AD | 1 |
| Pericole, FV | 1 |
| Carvalheira, JBC | 1 |
1 review available for metformin and Plasmacytoma
| Article | Year |
|---|---|
Metformin and blood cancers.
Topics: Body Mass Index; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Leukemia; Lymphoma | 2018 |